Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

T2 Biosystems, Inc. (TTOO)

1.57   -0.01 (-0.63%) 02-08 09:34
Open: 1.6 Pre. Close: 1.58
High: 1.6 Low: 1.57
Volume: 10,802 Market Cap: 11(M)

Technical analysis

as of: 2023-02-07 4:32:22 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 2.12     One year: 2.46
Support: Support1: 1.34    Support2: 1.11
Resistance: Resistance1: 1.81    Resistance2: 2.1
Pivot: 1.63
Moving Average: MA(5): 1.47     MA(20): 1.7
MA(100): 2.34     MA(250): 8.85
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 19.9     %D(3): 13
RSI: RSI(14): 48
52-week: High: 29.25  Low: 0.14
Average Vol(K): 3-Month: 177 (K)  10-Days: 202 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ TTOO ] has closed above bottom band by 40.9%. Bollinger Bands are 57.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 13 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.59 - 1.6 1.6 - 1.61
Low: 1.36 - 1.37 1.37 - 1.38
Close: 1.57 - 1.58 1.58 - 1.59

Company Description

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance to identify carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Headline News

Mon, 06 Feb 2023
2023-02-06 | NDAQ:TTOO | Press Release | T2 Biosystems Inc. - Stockhouse

Fri, 03 Feb 2023
T2 Biosystems Reports Granting of Inducement Award - InvestorsObserver

Tue, 24 Jan 2023
Why The T2 Biosystems Stock Fell By Over 3.5% (TTOO) - Pulse 2.0

Tue, 10 Jan 2023
Should Diagnostics & Research Stock T2 Biosystems Inc (TTOO) Be in Your Portfolio Tuesday? - InvestorsObserver

Fri, 30 Dec 2022
TTOO, EDU and TAL among premarket gainers - Seeking Alpha

Wed, 28 Dec 2022
Can T2 Biosystems Inc (TTOO) Stock Rise to the Top of Healthcare Sector Wednesday? - InvestorsObserver

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Diagnostics & Research
Shares Out. 166 (M)
Shares Float 7 (M)
% Held by Insiders 2.3 (%)
% Held by Institutions 5.5 (%)
Shares Short 607 (K)
Shares Short P.Month 313 (K)

Stock Financials

EPS -0.39
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.05
Profit Margin (%) -220.1
Operating Margin (%) -190.1
Return on Assets (ttm) -55.3
Return on Equity (ttm) 0
Qtrly Rev. Growth -11.7
Gross Profit (p.s.) -0.09
Sales Per Share 0.16
EBITDA (p.s.) -0.31
Qtrly Earnings Growth 0
Operating Cash Flow -44 (M)
Levered Free Cash Flow -23 (M)

Stock Valuations

PE Ratio -4.1
PEG Ratio 0
Price to Book value 26.33
Price to Sales 9.51
Price to Cash Flow -5.97

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.